Subscribe
-
2021 Year
COVID-19 vaccine Convidecia, MCV2 and MCV4 received approval -
2020 YearDeveloped COVID-19 vaccine Convidecia; Successfully listed on STAR market of the Shanghai Stock Exchange
-
2019 Year
NDA for MCV2 was accepted by NMPA; Listed on the Main Boary of HKEx; NDA for MCV4 was granted with Priority Review designation -
2018 YearCompleted commissioning of commercial manufacturing facility； CTA approved for DTcP and PBPV； Completed phase Ⅲ clinical trials for MCV2 and MCV4； Filed CTA for Pcv13i；
-
2017 Year
Obtained NDA approval of Ad5-EBOV in China -
2016 YearCompleted Ad5-EBOV Phase II clinical trial in Sierra Leone;
Submitted CTA of PBPV
-
2015 YearPilot facility passed EMA's QP inspection;
Obtained MCV2 & MCV4 CTA approvals -
2014 YearFiled CTA for DTcP candidates;
Obtained CTA approval of Ad5-EBOV and initiated clinical trial -
2013 YearFiled CTA for MCV2 & MCV4
-
2012 YearCompleted commissioning of pilot facility designed to meet the GMP
-
2009 Year
Incorporated and registered in Tianjin, China
